NCT02088073View on ClinicalTrials.gov

Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

PHASE3CompletedINTERVENTIONAL

Enrollment

258

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

January 31, 2015

Conditions

Hyperkalemia

Interventions

DRUG

Sodium zirconium cyclosilicate

Sodium zirconium cyclosilicate

DRUG

Placebo

Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)

Trial Locations (46)

Unknown

Anniston

Huntsville

Scottsboro

Phoenix

Tempe

Hawaiian Gardens

Los Angeles

Paramount

Riverside

Atlantis

Bradenton

Brandon

Brooksville

DeLand

Edgewater

Miami

Miami Lakes

New Smyrna Beach

Ocala

Summerfield

Tampa

Winter Park

Columbus

Decatur

Evergreen Park

Joliet

Shreveport

Auburn

Chesterfield

Kansas City

Las Vegas

Flushing

Altoona

Providence

Orangeburg

Sumter

Chattanooga

San Antonio

Gosford

Woolloongabba

Heidelberg

Melbourne

Parkville

Meyerspark

Port Elizabeth

Somerset West

All Listed Sponsors

lead

ZS Pharma, Inc.

INDUSTRY

NCT02088073 - Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia. | Biotech Hunter | Biotech Hunter